Actin-binding protein anillin (ANLN) is primarily involved in the cytokinesis and known to be dysregulated in many
cancers including
gastric cancer (GC). However, the regulation and clinical significance of ANLN in GC are far less clear. In the present study, we aimed to investigate the clinical significance and possible regulators of ANLN in GC. We have identified the Wnt/β-
catenin associated regulation of ANLN by analyzing the in vitro perturbed β-
catenin mRNA expression profiles. Investigating the gastric
tumors from publicly available genome-wide
mRNA expression profiles, we have identified the over expression of ANLN in gastric
tumors. Association between ANLN expression and clinical characteristics of GC showed elevated expression in intestinal type GC. Performing a single sample prediction method across GC
mRNA expression profiles, we have identified the over expression of ANLN in proliferative type gastric
tumors compared to the invasive and metabolic type gastric
tumors. In silico pathway prediction analysis revealed the association between Wnt/β-
catenin signaling and ANLN expression in gastric
tumors. Our results highlight that expression of a Wnt/β-
catenin responsive gene ANLN in GC is a molecular predictor of intestinal and proliferative type gastric
tumors.